New heart procedure could reduce transplants in End-Stage heart failure patients

NCT ID NCT07332871

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new approach for people with end-stage heart failure and permanent atrial fibrillation who are waiting for a heart transplant or heart pump. Participants will receive either a standard implantable defibrillator (ICD) alone or an ICD plus a special pacing lead and a targeted ablation to regularize the heart's rhythm. The goal is to see if the combined procedure lowers the risk of death, heart failure hospitalizations, or the need for urgent transplant over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Left bundle branch pacing (LBBP) lead and atrioventricular junction (AVJ) ablation procedure, combined with an implantable cardioverter-defibrillator (ICD)

What this could lead to

If successful, this combined procedure could reduce deaths and hospitalizations in end-stage heart failure patients with atrial fibrillation, potentially delaying the need for heart transplant or LVAD.

What could go wrong

This is a relatively small, early-stage trial (120 participants) with a 1-year follow-up, so results may not apply to all patients. The procedure carries risks such as bleeding, infection, or heart rhythm complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

advanced heart failure atrial fibrillation heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Division of Cardiology, Yonsei University College of Medicine.

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••